Effects of telitacicept and belimumab on systemic lupus erythematosus: a systematic review and meta-analysis
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract B cell-targeted therapies play an important role in systemic lupus erythematosus (SLE). Belimumab targets B lymphocyte stimulator (BLyS), whereas telitacicept inhibits both BLyS and APRIL. Although both drugs have demonstrated clinical efficacy in SLE, comparative benefits and risks of telitacicept versus belimumab remain unclear. We performed a systematic review and meta-analysis using indirect comparisons to compare their efficacy and safety. We searched 6 database for randomized controlled trials (RCTs) published up to November 1, 2025, without language restriction. Trials evaluating belimumab or telitacicept in adult SLE patients were included. Primary outcomes included SLE Responder Index 4 (SRI4), SRI7 response rates and decreasing SLEDAI score. Secondary outcomes included prednisone dose reduction, anti-dsDNA change, adverse events (AEs) and serious AEs. Data extraction and risk-of-bias assessment were performed independently by two reviewers. Analysis used RR with 95% CI, and heterogeneity was assessed by I 2 . Sensitivity, subgroup and publication-bias analyses were performed. 11 trials with telitacicept and belimumab involving 4303 participants were included. Compared with the belimumab group, telitacicept significantly increased the SRI4 response rate (relative risk [RR], 2.03, 95%CI, 1.65–2.49, p < 0.0001), SRI7 response rate (RR, 3.61, 95%CI, 1.57–8.29, p = 0.002) and decreased SLEDAI score (RR, 1.67, 95%CI, 1.41–1.97, p < 0.0001). Compared with belimumab, telitacicept exhibited a significant advantage in SRI4 response rate (p for interaction = 0.0002), without a significant difference in adverse events. Certainty of evidence ranged from moderate to high, but heterogeneity was present for some outcomes. Telitacicept improved SRI4 and SRI7 response rates, reducing disease activity and prednisone dosage, without a clear increase in infection risk compared with belimumab. Dual inhibition of BLyS and APRIL by telitacicept may offer an effective option for reducing SLE activity. Further large-scale, long-term head-to-head trials are needed to confirm these findings.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effects of telitacicept and belimumab on systemic lupus erythematosus: a systematic review and meta-analysis
- Date Crossref
- 27/11/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Zhejiang Chinese Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Dongzhimen Hospital pays non établi dans la noticeÉtablissement de santé
-
Hangzhou Hospital of Traditional Chinese Medicine pays non établi dans la noticeÉtablissement de santé
-
Ningbo University Affiliated Hospital pays non établi dans la noticeÉtablissement de santé
-
Ningbo First Hospital pays non établi dans la noticeÉtablissement de santé
-
Capital Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Changxing County Hospital of Traditional Chinese Medicine pays non établi dans la noticeÉtablissement de santé
-
The First Affiliated Hospital of Ningbo University pays non établi dans la noticeUniversité ou école supérieure
Zhejiang Chinese Medical University, Dongzhimen Hospital — Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine et Hangzhou Hospital of Traditional Chinese Medicine, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.